<DOC>
	<DOCNO>NCT01902680</DOCNO>
	<brief_summary>This pilot prospective biomedical study interventional type include 17 patient 24 month ( 12 month inclusion 12 month follow-up ) . The objective study verify focal therapy technique use ( help Koelis® system ) allow obtain optimal dosimetric coverage prostate target ( ie dose 160 Gy +-5 % deliver envelope isodose ) evaluate CT scan perform 30 day implantation .</brief_summary>
	<brief_title>Phase II Study Feasibility Focal Therapy Prostate Cancer Good Prognosis With Permanent I125 Localized Implant .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Men 18 year old 2 . Patient localized prostate cancer good prognosis ( AMICO classification ) , ie satisfy follow condition accord urologist medical record transmit : Lesion classify T1c T2a base digital rectal exam histologically proven diagnosis prostatic adenocarcinoma Gleason score ≤ 6 Serum Prostatic Specific Antigen ( PSA ) &lt; 10ng/ml 3 . Patient Multidisciplinary Consultative Meeting ( RCP ) adopt follow treatment option : active surveillance , brachytherapy , radical prostatectomy external radiation 4 . Patient good micturating function inclusion , define IPSS score &lt; 10 ( IPSS Questionnaire ) 5 . Patient result centralize PSA assay confirms serum level &lt; 10ng/ml 6 . Patient unique intracapsular character target area ( area treat ) confirm pre implantation multimodal MRI imaging ( ESUR Score ≥ 9 ) whose major axis size ≤ 20 mm 7 . Patient Gleason score target ≤ 6 ( 3 +3 ) confirm biopsy perform use KOELIS ® system derogatory criterion invasion entire core presence grade 4 perineural emboli 8 . Patients without history transurethral resection could significantly modify anatomy gland obstructive adenoma 9 . Patient accepts , end study , principle active surveillance rest gland treat area accord current standard protocol 10. WHO ≤ 2 11 . Patient life expectancy &gt; 10 year 12 . Informed consent obtain sign specific procedure study 13 . Patient affiliate social security regimen 1 . Image favour cross capsule , base preimplantation multimodal MRI ( stage T2 MRI ) 2 . Image favor invasion seminal vesicle , base preimplantation multimodal MRI ( stage T2 MRI ) 3 . Multifocal lesion ( ESUR ≥ 9/15 ) preimplantation multimodal MRI biopsy show cancerous nature 4 . Lesion large diameter ≥ 20mm , preimplantation multimodal MRI 5 . Patient require preimplantation hormonal treatment order reduce prostatic volume 6 . Patient current indication prostate brachytherapy , include significant limitation mobility hip , prostate volume great 60 cm3 ( measure planimetry MRI ) significant dysuria ( IPSS ≥ 10 ) 7 . Patient unable follow procedure , visit , examination describe study 8 . Patient absolute indication image test ( significant claustrophobia , wear heart valve , pacemaker , .. ) 9 . Man childbearing age want follow instruction sexual activity condom use day follow treatment brachytherapy / unwilling hold ( partner ) effective contraception duration study 10 . Any concomitant previous malignant disease past five year exception superficial basal cell carcinoma nonmetastatic skin 11 . Any prior systemic chemotherapy within 5 year prior inclusion malignant disease medical history 12 . Any coexist medical condition opinion investigator could risk study 13 . Patient protect law</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate cancer , permanent implant brachytherapy , image fusion , focal therapy , active surveillance</keyword>
</DOC>